Nothing Special   »   [go: up one dir, main page]

NL300690I2 - Lurasidon hydrochloride - Google Patents

Lurasidon hydrochloride

Info

Publication number
NL300690I2
NL300690I2 NL300690C NL300690C NL300690I2 NL 300690 I2 NL300690 I2 NL 300690I2 NL 300690 C NL300690 C NL 300690C NL 300690 C NL300690 C NL 300690C NL 300690 I2 NL300690 I2 NL 300690I2
Authority
NL
Netherlands
Prior art keywords
lurasidone hydrochloride
lurasidone
hydrochloride
Prior art date
Application number
NL300690C
Other languages
English (en)
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300690(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of NL300690I2 publication Critical patent/NL300690I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300690C 2005-05-26 2014-09-16 Lurasidon hydrochloride NL300690I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja) 2005-05-26 2006-05-26 医薬品組成物

Publications (1)

Publication Number Publication Date
NL300690I2 true NL300690I2 (nl) 2017-11-02

Family

ID=37452103

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300690C NL300690I2 (nl) 2005-05-26 2014-09-16 Lurasidon hydrochloride

Country Status (22)

Country Link
US (5) US8729085B2 (nl)
EP (2) EP2422783B1 (nl)
JP (2) JP4733120B2 (nl)
KR (2) KR101552033B1 (nl)
CN (2) CN101184489B (nl)
AU (1) AU2006250340C1 (nl)
BR (2) BR122020005056B1 (nl)
CA (1) CA2606510C (nl)
CY (2) CY1114118T1 (nl)
DK (2) DK2422783T3 (nl)
ES (2) ES2408687T3 (nl)
FR (1) FR14C0069I2 (nl)
HK (1) HK1108379A1 (nl)
HU (1) HUS1400051I1 (nl)
LU (1) LU92550I2 (nl)
MX (1) MX2007014872A (nl)
NL (1) NL300690I2 (nl)
PL (1) PL1884242T3 (nl)
PT (1) PT1884242E (nl)
RU (1) RU2398586C3 (nl)
SI (1) SI1884242T1 (nl)
WO (1) WO2006126681A1 (nl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123678A1 (ja) * 2005-05-18 2006-11-23 Dainippon Sumitomo Pharma Co., Ltd. ドロキシドパを含有する安定な錠剤
PL1884242T3 (pl) 2005-05-26 2013-09-30 Sumitomo Dainippon Pharma Co Ltd Kompozycja farmaceutyczna zawierająca lurasidon
KR20100121483A (ko) 2008-02-11 2010-11-17 다이닛본 스미토모 세이야꾸 가부시끼가이샤 용출성이 개선된 정제
EP2308511B1 (en) * 2008-06-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
JP5694773B2 (ja) * 2008-09-30 2015-04-01 テバ製薬株式会社 圧縮成型製剤およびその製造方法
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) * 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
WO2013014665A1 (en) 2011-07-28 2013-01-31 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN106074414B (zh) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) * 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EA201991007A1 (ru) * 2016-11-02 2019-08-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
PL3772992T3 (pl) 2018-04-10 2022-10-31 Freshfoodz Gmbh Sposób konserwowania posiłku przygotowanego przez podgrzewanie i dostarczania żywienia zbiorowego
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2022042646A1 (zh) * 2020-08-26 2022-03-03 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
CN116615184A (zh) * 2020-12-23 2023-08-18 住友制药株式会社 口服固体制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ATE226819T1 (de) 1995-02-28 2002-11-15 Aventis Pharma Inc Arzneizubereitungen für piperidinalkanolderivate
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
BR9814090A (pt) 1997-10-20 2000-10-03 Dainippon Pharmaceutical Co Composição de drogas rapidamente solúvel
JP4063386B2 (ja) 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1611881A1 (en) * 1999-03-31 2006-01-04 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2001076557A1 (fr) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Preparations a liberation prolongee
WO2002024166A1 (fr) * 2000-09-22 2002-03-28 Sumitomo Pharmaceuticals Company, Limited Preparations orales dotees de bonnes caracteristiques de desagregation
DE60236418D1 (de) 2001-03-19 2010-07-01 Dainippon Sumitomo Pharma Co Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003257589A1 (en) * 2002-08-22 2004-03-11 Sumitomo Pharmaceuticals Company, Limited Remedy for integration dysfunction syndrome
EP1536788A1 (en) 2002-08-30 2005-06-08 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2004078173A1 (ja) 2003-02-05 2004-09-16 Shionogi & Co., Ltd. 溶出性の改善された錠剤
SI3395338T1 (sl) 2003-09-12 2019-08-30 Amgen Inc., Hitrotopna formulacija, ki vsebuje cinakalcet HCL
JP4740740B2 (ja) 2003-12-09 2011-08-03 大日本住友製薬株式会社 薬物含有粒子および該粒子を含む固形製剤
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
PL1884242T3 (pl) 2005-05-26 2013-09-30 Sumitomo Dainippon Pharma Co Ltd Kompozycja farmaceutyczna zawierająca lurasidon

Also Published As

Publication number Publication date
EP1884242B1 (en) 2013-04-17
DK2422783T3 (en) 2015-05-11
BR122020005056A2 (nl) 2010-11-23
EP1884242A1 (en) 2008-02-06
KR20080012306A (ko) 2008-02-11
EP2422783A1 (en) 2012-02-29
BRPI0611409B8 (pt) 2021-05-25
JP4733120B2 (ja) 2011-07-27
AU2006250340B2 (en) 2012-02-09
US8883794B2 (en) 2014-11-11
BRPI0611409A8 (pt) 2015-12-15
CA2606510C (en) 2014-07-22
FR14C0069I2 (fr) 2015-11-20
RU2398586C2 (ru) 2010-09-10
US9555027B2 (en) 2017-01-31
SI1884242T1 (sl) 2013-07-31
KR101380088B1 (ko) 2014-04-10
CN101184489B (zh) 2011-01-19
WO2006126681A1 (ja) 2006-11-30
JP5285105B2 (ja) 2013-09-11
LU92550I2 (fr) 2015-11-02
PL1884242T3 (pl) 2013-09-30
CN102048734A (zh) 2011-05-11
ES2535478T3 (es) 2015-05-12
BRPI0611409B1 (pt) 2020-12-29
FR14C0069I1 (fr) 2014-10-24
JPWO2006126681A1 (ja) 2008-12-25
JP2011126915A (ja) 2011-06-30
CA2606510A1 (en) 2006-11-30
ES2408687T3 (es) 2013-06-21
US20140235651A1 (en) 2014-08-21
MX2007014872A (es) 2008-02-15
RU2007148997A (ru) 2009-07-10
US20090143404A1 (en) 2009-06-04
BR122020005056A8 (pt) 2022-11-22
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
US20180161322A1 (en) 2018-06-14
BRPI0611409A2 (pt) 2010-11-23
KR20130122019A (ko) 2013-11-06
EP2422783B1 (en) 2015-04-08
AU2006250340A1 (en) 2006-11-30
US9907794B2 (en) 2018-03-06
HK1108379A1 (en) 2008-05-09
US20150265611A1 (en) 2015-09-24
RU2398586C3 (ru) 2017-10-04
US20150056284A1 (en) 2015-02-26
CN102048734B (zh) 2013-11-20
US8729085B2 (en) 2014-05-20
HUS1400051I1 (hu) 2016-10-28
CN101184489A (zh) 2008-05-21
KR101552033B1 (ko) 2015-09-09
DK1884242T3 (da) 2013-05-06
PT1884242E (pt) 2013-05-21
AU2006250340C1 (en) 2014-06-12
BR122020005056B1 (pt) 2023-01-10
EP1884242A4 (en) 2009-07-01
CY1114118T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
NL300690I2 (nl) Lurasidon hydrochloride
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE602005011997D1 (de) Hren dafür
DE602006018521D1 (de) Hren dafür
DE502005004671D1 (de) Polyamid-EVA Mischungen
DE502006003394D1 (de) Lehnenklappung
DE602006012066D1 (de) Daraus
DE502006008475D1 (de) Wasserpumpenflügelrad
DE602006019046D1 (de) Türschliesservorrichtung
ATE549324T1 (de) Tetrahydrobenzoxazine
DE502006005667D1 (de) Gelenklager
DK1856051T3 (da) Amorft lercanidipinhydrochlorid
DE602005006405D1 (de) Maisabstreifer
DE502006006857D1 (de) Wingungserregern
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE602006002071D1 (de) Schiffandockseinrichtung
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE602005003547D1 (de) Fahrradantriebsnabe
DE502006006589D1 (de) Teils
ATE485368T1 (de) Hiv - impfung
DE502006004302D1 (de) Verschlusskappe
DE502006003147D1 (de) Verbundgußplatte
DE102005052834B8 (de) Punktschweißklebverbindung